An Insight into Advances in Developing Nanotechnology Based Therapeutics, Drug Delivery, Diagnostics and Vaccines: Multidimensional Applications in Tuberculosis Disease Management

Author:

Chopra Hitesh1ORCID,Mohanta Yugal Kishore2ORCID,Rauta Pradipta Ranjan3,Ahmed Ramzan24ORCID,Mahanta Saurov5ORCID,Mishra Piyush Kumar6,Panda Paramjot3ORCID,Rabaan Ali A.789ORCID,Alshehri Ahmad A.10ORCID,Othman Basim11,Alshahrani Mohammed Abdulrahman10,Alqahtani Ali S.12,AL Basha Baneen Ali13,Dhama Kuldeep14ORCID

Affiliation:

1. Chitkara College of Pharmacy, Chitkara University, Rajpura 140401, Punjab, India

2. Nanobiotechnology and Translational Knowledge Laboratory, Department of Applied Biology, School of Biological Sciences, University of Science and Technology Meghalaya (USTM), Techno City, 9th Mile, Ri-Bhoi, Baridua 793101, Meghalaya, India

3. School of Biological Sciences, AIPH University, Bhubaneswar 754001, Odisha, India

4. Department of Physics, Faculty of Science, Kasetsart University, Bangkok 10900, Thailand

5. National Institute of Electronics and Information Technology (NIELIT), Guwahati Centre, Guwahati 781008, Assam, India

6. Department of Botany, B. N. College, Dhubri 783324, Assam, India

7. Molecular Diagnostic Laboratory, Johns Hopkins Aramco Healthcare, Dhahran 31311, Saudi Arabia

8. College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia

9. Department of Public Health and Nutrition, The University of Haripur, Haripur 22610, Pakistan

10. Department of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Najran University, Najran 61441, Saudi Arabia

11. Department of Public Health, Faculty of Applied Medical Sciences, Albaha University, Albaha 65779, Saudi Arabia

12. Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Khalid University, Abha 61481, Saudi Arabia

13. Laboratory Department, King Fahad Specialist Hospital, Dammam 32253, Saudi Arabia

14. Division of Pathology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly 243122, Uttar Pradesh, India

Abstract

Tuberculosis (TB), one of the deadliest contagious diseases, is a major concern worldwide. Long-term treatment, a high pill burden, limited compliance, and strict administration schedules are all variables that contribute to the development of MDR and XDR tuberculosis patients. The rise of multidrug-resistant strains and a scarcity of anti-TB medications pose a threat to TB control in the future. As a result, a strong and effective system is required to overcome technological limitations and improve the efficacy of therapeutic medications, which is still a huge problem for pharmacological technology. Nanotechnology offers an interesting opportunity for accurate identification of mycobacterial strains and improved medication treatment possibilities for tuberculosis. Nano medicine in tuberculosis is an emerging research field that provides the possibility of efficient medication delivery using nanoparticles and a decrease in drug dosages and adverse effects to boost patient compliance with therapy and recovery. Due to their fascinating characteristics, this strategy is useful in overcoming the abnormalities associated with traditional therapy and leads to some optimization of the therapeutic impact. It also decreases the dosing frequency and eliminates the problem of low compliance. To develop modern diagnosis techniques, upgraded treatment, and possible prevention of tuberculosis, the nanoparticle-based tests have demonstrated considerable advances. The literature search was conducted using Scopus, PubMed, Google Scholar, and Elsevier databases only. This article examines the possibility of employing nanotechnology for TB diagnosis, nanotechnology-based medicine delivery systems, and prevention for the successful elimination of TB illnesses.

Publisher

MDPI AG

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Reference266 articles.

1. Global Tuberculosis Report 2020—Reflections on the Global TB Burden, Treatment and Prevention Efforts;Chakaya;Int. J. Infect. Dis.,2021

2. ECDC (2018). WHO 4% Annual Decrease Too Slow to End TB by 2030—Call for Europe’s Commitment to Increase Investment to End TB, ECDC.

3. Global Tuberculosis Targets and Milestones Set for 2016–2035: Definition and Rationale;Floyd;Int. J. Tuberc. Lung Dis.,2018

4. The Global Tuberculosis Epidemic and Progress in Care, Prevention, and Research: An Overview in Year 3 of the End TB Era;Floyd;Lancet Respir. Med.,2018

5. What We Know about Tuberculosis Transmission: An Overview;Churchyard;J. Infect. Dis.,2017

Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3